Contribute Try STAT+ Today

To tackle the runaway opioid addiction crisis, some drug makers have tried to make pain pills harder to abuse without changing the opioid molecule itself. This strategy often misfires: People figure out ways to bypass the abuse-resistant technology, allowing the unmodified opioid to enter the brain quickly, resulting in a euphoric high.

Clinical trial data released Tuesday bolsters the case for a different approach: Changing the opioid molecule itself. That’s what Nektar Therapeutics is doing with an experimental opioid tablet, known as NKTR-181, that’s designed to cross the blood-brain barrier more slowly. The goal: relieve pain, but with less euphoria and a lower potential for abuse.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.